Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia

Xiaomeng Sun, Jia Liu, Guang Wang, Xiaomeng Sun, Jia Liu, Guang Wang

Abstract

Background: This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia.

Methods: Type 2 diabetic patients (56) with microalbuminuria and hypertriglyceridemia aged 30 to 75 were randomly divided into the fenofibrate treatment group(n = 28) and the control group (n = 28) for 180 days. Urinary microalbumin /creatinine ratio (UACR) and other metabolic parameters were compared at baseline, during treatment and after treatment.

Results: After 180 days, the reduction of level of fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) between two groups showed no difference. In the treatment group, uric acid (UA) (296.42 ± 56.41 vs 372.46 ± 72.78), triglyceride (TG) [1.51(1.17, 2.06) vs 3.04(2.21, 3.29)], and UACR [36.45 (15.78,102.41) vs 129.00 (53.00, 226.25)] were significantly decreased compared with the baseline. The high-density lipoprotein cholesterol (HDL-C) levels were significantly increased (1.22 ± 0.26 vs 1.09 ± 0.24) compared with the baseline. The decrease in UACR [- 44.05(- 179.47, - 12.16) vs - 8.15(- 59.69, 41.94)]in treatment group was significantly higher compared with the control group. The decrease in UACR was positively associated with the decreases in TG (r = 0.447, P = 0.042) and UA (r = 0.478, P = 0.024) after fenofibrate treatment.

Conclusion: In the patients with hypertriglyceridemia and type 2 diabetes mellitus, fenofibrate can improve microalbuminuria and do not increase the deterioration of glomerular filtration rate.

Trial registration: ClinicalTrials.gov identifier: NCT02314533, 2014.12.9.

Keywords: Fenofibrate; Hypertriglyceridemia; Type 2 diabetes mellitus; Urinary albumin/creatinine ratio.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Correlations between the decrease in UACR and changes of TG and UA after fenofibrate treatment

References

    1. Locatelli F, Pozzoni P, Del VL. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol. 2004;15(Suppl 1):25–29. doi: 10.1097/01.ASN.0000093239.32602.04.
    1. Liu J, Lu R, Wang Y, Hu Y, Jia Y, Yang N, et al. PPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance. PPAR Res. 2016;2016:6232036.
    1. Liu J, Lu C, Li F, He W, He L, Hao Y, et al. PPAR α Agonist Fenofibrate Upregulates Tetrahydrobiopterin Level through Increasing the Expression of Guanosine Triphosphate Cyclohydrolase-I in Human Umbilical Vein Endothelial Cells. PPAR Res. 2011;2011:523520.
    1. Wang G, He L, Liu J, Yu J, Feng X, Li F, et al. Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia. Cardiovasc Ther. 2013;31:161–167. doi: 10.1111/j.1755-5922.2011.00307.x.
    1. Keech A, Drury P, Davis TM, Davis TM, Donoghoe M, Whiting M, et al. Protection against nephropathy with fenofibrate in type 2 diabetes mellitus: the FIELD study. Circulation. 2009;120:419–420.
    1. Zambon A, Cusi K. The role of fenofibrate in clinical practice. Diab Vasc Dis Re. 2007;4:15–20. doi: 10.3132/dvdr.2007.053.
    1. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Lawrence AL, Endou H, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574. doi: 10.1056/NEJMoa1001282.
    1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(Suppl 1):67–74. doi: 10.2337/dc13-S067.
    1. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007;27:195–207. doi: 10.1016/j.semnephrol.2007.01.012.
    1. Thompson J, Wilson P, Brandewie K, Taneja D, Schaefer L, Mitchell B, et al. Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathol. 2011;179:1179–1187. doi: 10.1016/j.ajpath.2011.05.016.
    1. Chung S, Park CW. Role of peroxisome proliferator-activated receptor a in diabetic nephropathy. Diabetes Metab J. 2011;5:327–336. doi: 10.4093/dmj.2011.35.4.327.
    1. Kintscher U, Lyon C, Wakino S, Bruemmer D, Feng X, Goetze S, et al. PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth musclecells by interacting with Smad4. Circ Res. 2002;91:35–44. doi: 10.1161/01.RES.0000046017.96083.34.
    1. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. Diabetologia. 2000;43:1435–1438. doi: 10.1007/s001250051551.
    1. Cosentino F, Hurlimann D, Delli Gatti C, Chenevard R, Blau N, Channon KM, et al. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart. 2007;94:487–492. doi: 10.1136/hrt.2007.122184.
    1. Xu N, Wang Q, Jiang S, Xie L, Chen J, Zhou S, et al. Fenofibrate improves vascular endothelial function and contractility in diabetic mice. Redox Biol. 2019;20:87–97. doi: 10.1016/j.redox.2018.09.024.
    1. Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, et al. PPAR alpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 2006;69:1511–1517. doi: 10.1038/sj.ki.5000209.
    1. Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, et al. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuatesdiabetic nephropathy in db/db mice. Diabetes. 2007;56:2036–2045. doi: 10.2337/db06-1134.
    1. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in the placebo controlled study in type 2 diabetes: results from the diabetes atherosclerosis intervention study (DAIS) Am J Kidney Dis. 2005;45:485–493. doi: 10.1053/j.ajkd.2004.11.004.
    1. Smulders YM, Van Eeden AE, Stehouwer CDA, Weijers RN, Slaats EH, Silberbusch J. Can reduction of hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Investig. 1997;27:997–1002. doi: 10.1046/j.1365-2362.1997.2330779.x.
    1. Frazier R, Mehta R, Cai X, Lee JW, Napoli S, et al. Associations of Fenofibrate therapy with incidence and progression of CKD in patients with type 2 diabetes. Kidney Int Rep. 2018;4:94–102. doi: 10.1016/j.ekir.2018.09.006.
    1. Hottelart C, el Esper N, Achard JM, Pruna A, Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie. 1999;20:41–44.
    1. Ansquer JC, Dalton RN, Caussé E, Crimet D, Le Malicot K, Foucher C. Effect of Fenofibrate on Kidney Function: A 6-Week Randomized. Am J Kidney Dis. 2008;51:904–913. doi: 10.1053/j.ajkd.2008.01.014.
    1. Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the action to control cardiovascular risk in diabetes (ACCORD) experience. Diabetologia. 2012;55:1641–1650. doi: 10.1007/s00125-012-2524-2.
    1. Jung JY, Choi Y, Suh CH, Yoon D, Kim HA. Effect of fenofibrate on uric acid level in patients with gout. Sci Rep. 2018;8:16767. doi: 10.1038/s41598-018-35175-z.
    1. Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70. doi: 10.1016/j.phrs.2015.09.012.
    1. Feher MD, Hepburn AL, Hogarth MB. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology. 2003;42:321–325. doi: 10.1093/rheumatology/keg103.
    1. Lee YH, Lee CH, Lee J. Effect of fenofibrate in combination with urate lowering agents in patients with gout. Korean J Intern Med. 2006;21:89–93. doi: 10.3904/kjim.2006.21.2.89.
    1. Noguchi Y, Tatsuno I, Suyama K, Shibata T, Yoshida T, Otsuka Y, et al. Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients. Atheroscler Thromb. 2004;11:335–340. doi: 10.5551/jat.11.335.
    1. Uetake D, Ohno I, Ichida K, Yamaguchi Y, Saikawa H, Endou H, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med. 2010;49:89–94. doi: 10.2169/internalmedicine.49.2597.
    1. Latif H, Iqbal A, Rathore R, Butt NF. Correlation between serum uric acid level and microalbuminuria in Type-2 diabetic nephropathy. Pak J Med Sci. 2017;33:1371–1375. doi: 10.12669/pjms.336.13224.
    1. Neupane S, Dubey RK, Gautam N, Agrawal KK, Jayan A, Shrestha S, et al. Association between serum uric acid, urinary albumin excretion, and glycated hemoglobin in type 2 diabetic patient. Niger Med J. 2016;57:119–123. doi: 10.4103/0300-1652.182074.
    1. Behradmanesh S, Horestani MK, Baradaran A, Nasri H. Association of serum uric acid with proteinuria in type 2 diabetic patients. J Res Med Sci. 2013;18:44–46.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren